Cannabis and Psoriasis

Plain-language summary

Psoriasis is a chronic autoimmune disease in which the immune system drives skin cells to multiply too fast, producing thick, scaly, often itchy plaques. The IL-23 / IL-17 inflammatory pathway is central to the disease ^[1].

Cannabis contains compounds — THC, CBD, CBG and others — that interact with the endocannabinoid system, which is present in human skin and helps regulate inflammation, keratinocyte (skin cell) proliferation, and immune activity ^[2]. That biological overlap is why researchers are interested. It is not, by itself, evidence that cannabis treats psoriasis.

As of late 2024, no cannabinoid product is approved by the FDA, EMA, or MHRA for psoriasis. Existing human evidence is limited to small case series, surveys, and a handful of small trials on related skin conditions. The strongest claims you see online — that CBD oil 'clears' psoriasis, that cannabis is anti-inflammatory enough to replace biologics — are not supported by the data we have. No data

This article is not medical advice. Psoriasis can range from a cosmetic annoyance to a disabling, joint-destroying systemic disease. Decisions about treatment should be made with a dermatologist or rheumatologist who knows your case.

What probably works

Honestly: in the cannabis-for-psoriasis space, nothing yet qualifies as 'probably works' by the standards of evidence-based medicine.

There are no large randomized controlled trials, no replicated positive trials, and no regulatory approvals. Anyone telling you otherwise is selling something.

The closest thing to a defensible 'probably' is symptomatic relief of itch and sleep disruption in people who use cannabis for general reasons — but even this rests on indirect evidence from other itch conditions and from cannabis's known effects on sleep, not on psoriasis-specific trials. Weak / limited

What might work (weak / preliminary evidence)

Topical cannabinoids for plaque appearance and itch. A small 2019 open-label study by Palmieri et al. applied a CBD-enriched ointment to psoriasis, atopic dermatitis, and scarring lesions and reported improvements in skin hydration, elasticity, and itch over three months ^[3]. The study had no control group, no blinding, and a mixed-condition cohort — so it is hypothesis-generating, not confirmatory. Weak / limited

Cannabinoids and keratinocyte proliferation. In cell-culture work, THC, CBD, CBN, and CBG all slowed the proliferation of human keratinocytes — the runaway-cell-division problem at the heart of plaque formation ^[4]. This is mechanistically suggestive but very far from clinical proof. Many compounds suppress keratinocytes in a dish without doing anything useful on a human elbow. Weak / limited

Psoriatic arthritis pain. There is moderate evidence that cannabis can reduce some forms of chronic pain ^[5]. Whether that generalizes to psoriatic arthritis specifically has not been well studied. Weak / limited

Itch (pruritus). Cannabinoid receptors are expressed on sensory neurons and skin immune cells, and small trials of topical cannabinoid-related compounds (e.g. palmitoylethanolamide) have shown antipruritic effects in conditions like uremic itch and atopic dermatitis ^[2]. Direct psoriasis-itch trials are essentially absent. Weak / limited

What doesn't work, or has no good evidence

• Smoking cannabis to treat psoriasis. No clinical evidence supports this, and smoking introduces its own inflammatory load. Tobacco smoking is an established risk factor for psoriasis severity ^[6]; cannabis smoke shares many combustion products. No data
• Oral CBD as a standalone psoriasis treatment. No published RCTs. Confident marketing claims are not backed by trial data. No data
• 'High-myrcene' or 'indica' strains for autoimmune disease. This is folklore, not pharmacology. The indica/sativa label does not reliably predict chemistry or clinical effect Disputed, and no terpene has been shown to modify psoriasis in humans. No data
• Replacing biologics with cannabis. No data. Stopping a working biologic to switch to CBD is a decision with real, measurable downside (disease flare, joint damage in psoriatic arthritis) and no demonstrated upside.

What we don't know

A lot. Open questions include:

• Whether topical CBD or THC at any specific concentration outperforms a basic moisturizer in a blinded trial.
• Whether cannabinoids modulate the IL-23/IL-17 axis in humans the way they appear to in some animal models.
• Whether oral or inhaled cannabis has any disease-modifying effect, or only changes how patients feel about their disease via pain, itch, sleep, and mood.
• Whether long-term cannabis use interacts (positively or negatively) with methotrexate, cyclosporine, or biologics. CBD is a known inhibitor of CYP enzymes and can raise levels of some co-administered drugs ^[7].
• Whether specific minor cannabinoids (CBG, CBC) or non-cannabinoid skin lipids are doing the work in topical formulations.

Until there are properly powered, placebo-controlled trials, anyone giving you confident numbers is guessing.

Comparison with standard treatments

For context, here is what does have strong evidence in psoriasis:

• Topical corticosteroids and vitamin D analogs (calcipotriol): first-line for mild-to-moderate plaque psoriasis, with decades of trial data ^[1]. Strong evidence
• Narrowband UVB phototherapy: effective for widespread disease. Strong evidence
• Methotrexate, cyclosporine, acitretin: older systemics, well-studied, with known toxicities. Strong evidence
• Biologics targeting TNF-α (adalimumab), IL-17 (secukinumab, ixekizumab), or IL-23 (guselkumab, risankizumab): can produce PASI-90 or PASI-100 responses (near-complete clearance) in a majority of patients in pivotal trials ^[8]. Strong evidence

No cannabis product currently comes within an order of magnitude of these response rates in published data. That is the honest comparison.

Risks and interactions

• Drug interactions. CBD inhibits CYP3A4 and CYP2C19 and can raise blood levels of drugs metabolized by these pathways. Cyclosporine and some immunosuppressants are CYP3A4 substrates ^[7]. This matters for psoriasis patients on systemics.
• Smoke exposure. Combusted cannabis irritates airways and may worsen general inflammatory burden; tobacco co-use is associated with more severe psoriasis ^[6].
• Topical contact dermatitis. Cannabinoid topicals often contain carrier oils, fragrances, and preservatives that can themselves provoke skin reactions — especially on already-inflamed psoriatic skin.
• Product quality. The CBD market is poorly regulated. FDA testing has repeatedly found products that contain less (or more) cannabinoid than labeled, plus contaminants ^[9].
• Replacing effective therapy. The biggest risk is opportunity cost: choosing an unproven cannabis product over a proven treatment for moderate-to-severe disease, which can result in permanent joint damage in psoriatic arthritis.

This article is informational and is not medical advice. Talk to a dermatologist before changing your treatment.

Sources

How this page was made

Related

• Cannabis and Eczema — What the evidence actually says about cannabinoids, topical hemp products, and atopic derm...